(4-(trifluoromethyl)benzyl)zinc(II) bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(trifluoromethyl)benzyl)zinc(II) bromide
• 英文别名: 4-(trifluoromethyl)benzylzinc bromide；p-trifluoromethylbenzylzinc bromide；4-trifluoromethylbenzyl zinc(II) bromide
• 化学式: C₈H₆BrF₃Zn
• 分子量: 304.425
• InChiKey: PWQUDVHLOJEQHO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  (4-(trifluoromethyl)benzyl)zinc(II) bromide 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 4.33h， 生成 N-methyl-4-(3-(4-(trifluoromethyl)benzyl)pyrazin-2-yl)benzenesulfonamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

  公开号：

  WO2023146513A1
• 作为产物：
  描述：

  1-溴-三氟对二甲苯 在 三甲基氯硅烷 、 1,2-二溴乙烷 、 lithium chloride 、 锌 作用下， 以 四氢呋喃 为溶剂， 生成 (4-(trifluoromethyl)benzyl)zinc(II) bromide
  参考文献：
  名称：

  Highly Regioselective Three-Component Domino Heck–Negishi Coupling Reaction for the Functionalization of Purines at C6

  摘要：

  A highly regioselective three-component domino Heck-Negishi coupling reaction has been developed. Organozinc reagents are used to trap an alkylpalladium intermediate of olefins for a first example in the domino Heck reaction. This reaction is applicable to acrylates (or acrylamides) and purine compounds, producing a series of novel purine compounds with carbon substituents at the C6 position in moderate to good yields.

  DOI：

  10.1021/ol4032683

文献信息

• Vanilloid receptor ligands and their use in treatments
  申请人：Gore Keshav Vijay

  公开号：US20060084640A1

  公开（公告）日：2006-04-20

  Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  治疗性苯并咪唑及含有它们的组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合征、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症症状、炎症性疼痛及相关的过敏性疼痛和触痛、神经痛及相关的过敏性疼痛和触痛、糖尿病性神经病痛、烧灼性疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、消化或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、毛发生长、血管运动性或过敏性鼻炎、支气管疾病或膀胱疾病。
• Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy
  作者：Zhisong Wang、Yan Gao、Lei He、Shuhao Sun、Tingting Xia、Lu Hu、Licheng Yao、Liangliang Wang、Dan Li、Hui Shi、Xuebin Liao

  DOI：10.1021/acs.jmedchem.1c00179

  日期：2021.6.10

  Activation of the toll-like receptors 7 and 8 has emerged as a promising strategy for cancer immunotherapy. Herein, we report the design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds 24e and 25a significantly induced the secretion of IFN-α, IFN-γ

  Toll 样受体 7 和 8 的激活已成为癌症免疫治疗的一种有前途的策略。在此，我们报告了一系列基于吡啶并 [3,2 - d ] 嘧啶的 Toll 样受体 7/8 双激动剂的设计和合成，这些激动剂对 TLR7 和 TLR8 表现出强效且接近等效的激动活性。在体外，化合物24e和25a在人外周血单核细胞测定中显着诱导 IFN-α、IFN-γ、TNF-α、IL-1β、IL-12p40 和 IP-10 的分泌。在体内，化合物24e、24m和25a通过重塑肿瘤微环境显着抑制 CT26 荷瘤小鼠的肿瘤生长。此外，化合物24e，24m和25a显着提高了 PD-1/PD-L1 阻断的抗肿瘤活性。特别是，化合物24e与抗 PD-L1 抗体结合导致肿瘤完全消退。这些结果表明，TLR7/8 激动剂（24e、24m和25a）作为单药或与 PD-1/PD-L1 阻断剂联合用于癌症免疫治疗具有巨大潜力。
• C( <i>sp</i> ³ )−C( <i>sp</i> ³ ) Bond Formation <i>via</i> Electrochemical Alkoxylation and Subsequent Lewis Acid Promoted Reactions
  作者：Enol López、Carlo Melis、Raúl Martín、Alessia Petti、Antonio Hoz、Ángel Díaz‐Ortíz、Adrian P. Dobbs、Kevin Lam、Jesús Alcázar

  DOI：10.1002/adsc.202100749

  日期：2021.10.5

  methodology for the C(sp3)−C(sp3) functionalisation of saturated N-heterocyclic systems is disclosed. First, aminal derivatives are generated through the anodic oxidation of readily accessible carboxylic acids. Then, in the presence of BF3 ⋅ OEt2, iminium ions are unmasked and rapidly alkylated by organozinc reagents under flow conditions. Secondary, tertiary and quaternary carbon centers have been successfully

  公开了用于饱和N-杂环系统的C( sp 3 )-C( sp 3 )官能化的两步无过渡金属方法。首先，氨基衍生物是通过容易获得的羧酸的阳极氧化产生的。然后，在 BF 3  ⋅ OEt 2存在下，亚胺离子在流动条件下被有机锌试剂暴露并迅速烷基化。使用这种方法已经成功地组装了二级、三级和四级碳中心。这种方法与药物发现特别相关，因为它增加了 C( sp 3)-在分子框架内迅速发挥功能。作为概念证明，我们的方法应用于肽和 API 的衍生化。
• Palladium-Catalyzed Cross-Coupling Reactions of Carboxylic Anhydrides with Organozinc Reagents
  作者：Donghui Wang、Zhaoguo Zhang

  DOI：10.1021/ol035801w

  日期：2003.11.1

  [reaction: see text] Negishi-type cross-coupling reaction was effected by employing organozincs and anhydrides or mixed anhydrides that formed in situ from sodium salts of the corresponding acids and ethyl chloroformate under the catalysis of palladium(0). A general method for preparing symmetrical/unsymmetrical ketones was developed.

  [反应：见正文] Negishi型交叉偶联反应是通过使用有机锌和酸酐或混合酸酐（由相应酸的钠盐和氯甲酸乙酯在钯（0）催化下原位形成）而进行的。开发了一种制备对称/不对称酮的通用方法。
• 新型EP4拮抗剂的合成及其在癌症和炎症中的用途
  申请人：湖北生物医药产业技术研究院有限公司

  公开号：CN113354585A

  公开（公告）日：2021-09-07

  本发明提出了一种有效拮抗EP4的新化合物，其为式I所示化合物，或者式I所示化合物的互变异构体、立体异构体、水合物、溶剂化物、药学可接受的盐或前药：其中：R1选自‑CH3、‑CHF2和‑CF3；R2选自C2‑C6烷基、C3‑C6环烷基、被卤素取代的C2‑C6烷基、被卤素取代的C3‑C6环烷基；R3选自氢、卤素、C1‑C2烷基、被氟取代的C1‑C2烷基；R4选自氢、卤素、C1‑C6烷基、C1‑C6烷氧基、被卤素取代的C1‑C6烷基、被卤素取代的C1‑C6烷氧基。